Severin, G. W. http://orcid.org/0000-0003-1189-7311
Fonslet, J.
Kristensen, L. K.
Nielsen, C. H.
Jensen, A. I.
Kjær, A. http://orcid.org/0000-0002-2706-5547
Mazar, A. P.
Johnston, K. http://orcid.org/0000-0002-0513-6869
Köster, U.
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (654002)
Michigan State University
Article History
Received: 21 July 2021
Accepted: 2 February 2022
First Online: 9 March 2022
Competing interests
: APM is a co-founder and employee of Monopar Therapeutics, Inc., which owns the hybridoma used to produce ATN-291. The authors declare no further competing interests related to this work.